etoposide has been researched along with Cancer of Prostate in 223 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (6.28) | 18.7374 |
| 1990's | 58 (26.01) | 18.2507 |
| 2000's | 99 (44.39) | 29.6817 |
| 2010's | 42 (18.83) | 24.3611 |
| 2020's | 10 (4.48) | 2.80 |
| Authors | Studies |
|---|---|
| Akunuri, R; Bhargava, SK; Bonam, SR; Kamal, A; Kumar, HMS; Naidu, VGM; Nayak, VL; Reddy, TS; Reddy, VG; Srihari, P | 1 |
| Fukada, J; Hongo, H; Kosaka, T; Mikami, S; Oya, M; Suzuki, Y | 1 |
| Briganti, S; Bruni, E; Capradossi, F; Corsi, F; Ghibelli, L; Pelliccia, A; Reichle, A; Torino, F; Traversa, E | 1 |
| Cheng, L; Qin, H; Tao, L; Wang, J; Wang, Y; Zhu, G | 1 |
| Alabi, BR; Liu, S; Stoyanova, T | 1 |
| Bando, Y; Fujisawa, M; Furukawa, J; Hara, T; Harada, K; Hirata, J; Jimbo, N; Nakano, Y; Okamura, Y; Terakawa, T; Ueki, H | 1 |
| Akino, Y; Mabuchi, N; Masai, N; Ogawa, K; Oh, RJ; Shiomi, H | 1 |
| Miralbell, R | 1 |
| Hieda, M; Higashiyama, S; Kikugawa, T; Maekawa, M; Miura, N; Saika, T; Taguchi, T; Watanabe, R | 1 |
| Aghebati-Maleki, L; Baradaran, B; Majidi, J; Malekghasemi, S | 1 |
| Ari, F; Erkisa, M; Khodadust, R; Ulku, I; Ulukaya, E; Yagci Acar, H; Yar, Y | 1 |
| Chao, OS; Goodman, OB | 1 |
| Erdelkamp, R; Hentrich, M; Stief, C; Tritschler, S | 1 |
| Ajdary, S; Ardestani, SK; Davoodi, J; Foroumadi, A; Safavi, M; Shakeri, R | 1 |
| Allan, E; Hanna, F; Khalafallah, AA; Prakash, A | 1 |
| Annala, M; Beltran, H; Chedgy, EC; Chi, KN; Donoghue, AJ; Fazli, L; Herberts, C; Hurtado-Coll, A; Konomura, S; Liew, J; Parimi, S; Ritch, E; Sboner, A; Sigouros, M; Struss, W; Vandekerkhove, G; Vergidis, J; Wyatt, AW | 1 |
| Cheng, WH; Ho, CH; Lee, WH; Tzou, KY | 1 |
| Rajput, SJ; Saroj, S | 1 |
| Chang, C; Chen, Y; Ding, XF; Huang, CK; Lee, SO; Li, G; Lin, SJ; Luo, J; Shan, YX; Wang, R; Yang, DR; Zhu, J | 1 |
| Bastide, C; Beuzeboc, P; Brenot-Rossi, I; Bruyère, F; Guy, L; Karsenty, G; Mongiat-Artus, P | 1 |
| Erbaykent-Tepedelen, B; Gonen-Korkmaz, C; Karamil, S; Korkmaz, KS | 1 |
| Dai, B; Lin, GW; Shen, YJ; Shi, GH; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y; Zhu, YP | 1 |
| Tang, D; Yan, J | 1 |
| Azabdaftari, G; Dalimov, Z; Ellis, L; Hu, Q; Kirk, JS; Ku, S; Lasorsa, E; Pili, R; Ramakrishnan, S; Schaarschuch, K; Wang, J | 1 |
| El-Schich, Z; Falck Miniotis, M; Gjörloff Wingren, A; Härkönen, P; Mölder, A; Tassidis, H | 1 |
| Fox, JL; Storey, A | 1 |
| Ala, U; Berger, AH; Carver, BS; Castillo-Martin, M; Chen, M; Cordon-Cardo, C; Guarnerio, J; Hobbs, RM; Ishikawa, T; Lunardi, A; Montironi, R; Nardella, C; Ng, C; Pandolfi, PP; Poliseno, L; Quarantotti, V; Seitzer, N; Signoretti, S; Taulli, R; Varmeh, S | 1 |
| Ayala, AG; Choi, EK; Divatia, M; Miles, BJ; Okoye, E; Ro, JY | 1 |
| Furr, JR; Mellis, AM; Slobodov, G | 1 |
| Bora, HK; Chaudhary, D; Khedgikar, V; Konwar, R; Kumar, A; Kushwaha, P; Mathur, V; Mishra, PR; Shukla, P; Teja, VB; Trivedi, R | 1 |
| Dobelbower, M; Donavanik, V; Gomella, L; Grignon, D; Hamstra, DA; Hartford, AC; Hunt, D; Jones, CU; Kerlin, KJ; Kim, H; Kuban, DA; Michalski, J; Moughan, J; Pienta, KJ; Rajan, R; Rosenthal, SA; Rotman, M; Sandler, H; Sartor, AO; Seider, M; Shipley, WU; Zeitzer, K | 1 |
| Asara, JM; Beck, AH; Cheng, L; Dai, X; Gan, W; Huang, J; Inuzuka, H; Li, Z; Liu, P; Lunardi, A; Pandolfi, PP; Sun, Y; Varmeh, S; Wei, W; Zhang, J | 1 |
| Andrake, MD; Arora, S; Bodian, DL; Daly, MB; Dunbrack, RL; Egleston, BL; Giri, VN; Golemis, EA; Hall, MJ; Handorf, ED; Nicolas, E; Ross, EA; Serebriiskii, IG; Vockley, JG; Zhou, Y | 1 |
| Charette, N; Dupré, DJ; Kuang, YQ; Purcell, C; Young, B | 1 |
| Hirai, M; Kobayashi, Y; Konishi, T; Miyagawa, T; Nokubi, M; Saito, K; Washino, S | 1 |
| Buizen, L; Friedlander, M; Gebski, V; Grimison, P; Gurney, H; Kichenadasse, G; Lawrence, N; Lewis, C; Martin, A; Rosenthal, M; Singhal, N; Stockler, M; Thomson, D; Toner, G; Vasey, P; Wong, N; Wong, S; Yeung, A | 1 |
| Asakura, T; Nin, M; Okada, T; Satoh, M; Tsujihata, M; Yumiba, S | 1 |
| Apostolov, EO; Basnakian, AG; Pogribny, IP; Shah, SV; Tryndyak, V; Wang, X; Yin, X | 1 |
| Asbell, SO; Bae, K; Kerlin, KJ; Michalski, JM; Pienta, KJ; Rajan, R; Rosenthal, SA; Sandler, HM; Sobczak, ML | 1 |
| Ariu, L; Curigliano, G; de Braud, F; De Cobelli, O; De Pas, T; Detti, S; Matei, DV; Nolè, F; Rocco, B; Scardino, E; Spitaleri, G; Verweij, F; Zambito, S | 1 |
| Mavridis, K; Scorilas, A; Talieri, M; Thomadaki, H | 1 |
| Dowling, C; Gill, C; O'Neill, AJ; Watson, RW | 1 |
| Abrahamsson, PA; Dizeyi, N; Evans, S; Persson, J | 1 |
| Liu, S; Yamauchi, H | 1 |
| Allegro, R; Altieri, V; De Grande, G; Falsaperla, M; Melloni, D; Morgia, G; Napoli, M; Serretta, V; Siragusa, A | 1 |
| Hashimoto, T; Izumi, M; Matsubayashi, J; Ohori, M; Sakamoto, N; Tachibana, M | 1 |
| Bhattacharya, RK; Mukherjee, S; Roy, M | 1 |
| Eaton, JW; Grizzle, WE; Novakovic, KR; Sharma, PK; Singh, R; Singh, S | 1 |
| Ângelo, S; Moreira, JN; Pinto, AC; Simões, S | 1 |
| Feng, FY; Liu, P; Qin, Y; Shi, YK; Xing, PY | 1 |
| Essler, M; Krause, BJ; Maurer, T; Souvatzoglou, M; Treiber, U; Weirich, G | 1 |
| Deguchi, T; Fujita, Y; Ito, M; Kojima, K; Nozawa, Y | 1 |
| Azuma, H; Fujisue, Y; Ibuki, N; Inamoto, T; Katsuoka, Y; Komura, K; Koyama, K; Nomi, H; Takahara, K; Ubai, T; Uehara, H; Utimoto, S | 1 |
| Akashi, K; Akimoto, M; Hasegawa, T; Hirano, G; Izumi, H; Ke-Yong, W; Kohno, K; Kusaba, H; Matsumoto, K; Sasagiri, Y; Shimajiri, S; Yasuniwa, Y | 1 |
| Golshayan, A; Harrer, GW; Hussain, MH; Mills, GM; Smith, DC; Tangen, CM; Thompson, IM; Van Veldhuizen, PJ; Vogelzang, NJ | 1 |
| Brammer, JE; Lulla, P; Lynch, GR | 1 |
| Beuzeboc, P; Culine, S; Deplanque, G; Droz, JP; Fargeot, P; Ferlay, C; Fléchon, A; Gravis, G; Joly, F; Oudard, S; Perol, D; Pouessel, D; Priou, F; Zanetta, S | 1 |
| Constantinou, AI; Constantinou, C; Hyatt, JA; Neophytou, CM; Papas, KA; Vraka, P | 1 |
| Fadlalla, K; Katkoori, V; Manne, U; Mosley, L; Samuel, T; Turner, T | 1 |
| Hollingsworth, J; Koh, GY; Liu, Z; Russo, PS; Stout, RW; Zhang, F | 1 |
| Hu, N; Huang, W; Luo, L; Luo, Z; Tao, R; Xiao, ZX | 1 |
| Hayakawa, Y; Hirano, K; Iguchi, K; Ishii, K; Matsumoto, K; Sugimura, Y; Usui, S | 1 |
| McDonnell, TJ; Meyn, RE; Munshi, A | 1 |
| Daliani, DD; Logothetis, CJ; Papandreou, CN; Reyes, A; Thall, PF; Troncoso, P; Tu, SM; Wang, X | 1 |
| Akudugu, JM; Bohm, L; Serafin, AM | 1 |
| Ishida, E; Kishi, M; Konishi, N; Nakamura, M; Shimada, K; Yonehara, S | 2 |
| Dimtchev, A; Dritschilo, A; Jung, M; Rosenthal, D; Smulson, M; Soldatenkov, V; Trofimova, I | 1 |
| Benchekroun, A; Iken, A; Jira, M; Kasmaoui, el H; Nouini, Y; Zannoud, M | 1 |
| Naito, K | 1 |
| Cannon, MW; Jones, D; Kuebler, JP; Lee, SJ; Logothetis, CJ; Millikan, R; Thall, PF; Wade, J | 1 |
| Brodak, M; Louda, M; Moravek, P; Odrazka, K; Petera, J; Prosvic, P; Rydel, L; Simakova, E; Vaculikova, M; Veselsky, Z; Zoul, Z | 1 |
| Anderson, JS; Daniel, KG; Dou, QP; Gupta, P; Kazi, A; Zhong, Q | 1 |
| Chay, CH; Dunn, RL; Esper, P; Fardig, J; Olson, K; Pienta, KJ; Smith, DC | 1 |
| Einhorn, LH; Foster, RS; Henley, JD; Sheski, FD | 1 |
| Syed, S | 1 |
| Butts, JA; Greco, FA; Hainsworth, JD; Meluch, AA; Morrissey, LH; Raefsky, EL; Steis, RG | 1 |
| McConkey, DJ; Williams, SA | 1 |
| Coombes, KR; Gold, DL; Johnson, TJ; Logothetis, CJ; McDonnell, TJ; Meyn, RE; Spurgers, KB | 1 |
| Frank, R; Kelly, WK; Reuter, V; Scher, HI; Schwartz, L; Steineck, G | 1 |
| Asakuma, J; Asano, T; Hayakawa, M; Nanus, DM; Sumitomo, M | 1 |
| Alamanis, C; Constantinidis, C; Deliveliotis, C; Dimopoulos, MA; Giannopoulos, A; Gika, D; Kiamouris, C; Koutsilieris, M; Zervas, A | 1 |
| Hara, N; Kasahara, T; Katagiri, A; Kawasaki, T; Kimura, M; Morishita, H; Nishiyama, T; Saito, K; Saito, T; Sasagawa, T; Takahashi, K; Tanikawa, T; Tomita, Y | 1 |
| Conticello, C; De Maria, R; Messina, A; Patti, M; Pedini, F; Peschle, C; Stassi, G; Zerilli, M; Zeuner, A | 1 |
| Abonour, R; Einhorn, LH; Houck, W; Vance, G | 1 |
| Roomans, GM; Salido, M; Vilches, J | 1 |
| Cook, A; Izawa, JI; Mack, DP; Moussa, M | 1 |
| Koochekpour, S; Lee, TJ; Luftig, RB; Sartor, O | 1 |
| Du, W; Fontana, J; Hussain, M; Vaishampayan, U | 1 |
| Battistel, C; Hartung, R; Kübler, HR; Lehmer, A; Paul, R; Treiber, U; van Randenborgh, H; Wagenpfeil, S; Wutzler, S | 1 |
| Hu, H; Ip, C; Jiang, C; Lü, J; Rustum, YM | 1 |
| Asano, K; Egawa, S; Hayashi, N; Manome, Y; Suzuki, H; Tanigawa, N; Yamamoto, T | 1 |
| Keefe, D; Myers, M; Olver, I | 1 |
| Mimata, H; Nomura, T; Nomura, Y; Yamasaki, M | 1 |
| Dolezal, J; Dolezel, M; Moravek, P; Odrazka, K; Petera, J; Prosvic, P; Simakova, E; Vaculikova, M; Vosmik, M; Zoul, Z | 1 |
| Abasolo, I; Calvo, A; Montuenga, LM | 1 |
| Garrett, MD; Mantoni, TS; Reid, G | 1 |
| Kitamura, Y; Komatsubara, S; Saito, T | 1 |
| Brown, E; Gronda, M; Gurfinkel, D; Hurren, R; Konopleva, M; Mawji, IA; Pellecchia, M; Pond, GR; Reed, JC; Schimmer, AD; Thomas, MP | 1 |
| Ellerhorst, J; Elsamman, E; Fukumori, T; Kanayama, HO; Kasai, T; Lotan, R; Nangia-Makker, P; Oka, N; Raz, A; Shono, M; Takenaka, Y | 1 |
| Antic, N; de Lanerolle, P; Gu, LZ; Hu, WY; Mehta, R; Turner, JR | 1 |
| Kim, BH; Lee, HM; Park, JO; Song, SY | 1 |
| Abramjuk, C; Jung, K; Krell, HW; Lein, M; Loening, SA; Rothaug, W | 1 |
| Bogdanos, J; Dimopoulos, P; Dimopoulos, T; Halapas, A; Karamanolakis, D; Katopodis, H; Koutsilieris, M; Lembessis, P; Milathianakis, C; Papageorgiou, E; Pissimissis, N; Pitulis, N; Sourla, A; Tenta, R | 1 |
| Batra, SK; Depreux, P; Henichart, JP; Johansson, SL; Lin, MF; Mimeault, M; Moore, E; Venkatraman, G | 1 |
| Atweh, GF; Mistry, SJ | 1 |
| Ling, MT; Wang, X; Wong, YC; Zhang, X | 1 |
| Kenna, T; Mattarollo, SR; Nicol, AJ; Nieda, M | 1 |
| Azuma, K; Hashine, K; Karashima, T; Kasahara, K; Miura, N; Nakatsuzi, H; Numata, K; Sumiyoshi, Y | 1 |
| Gonzalez, JL; Salido, M; Vilches, J | 1 |
| Calvo, A; de las Rivas, J; Gonzalez-Moreno, O; Nguewa, P; Segura, V; Serrano, D | 1 |
| Dutt, SS; Gao, AC; Lee, SO; Liao, H; Nadiminty, N; Pinder, E | 1 |
| Cooney, KA; Dunn, RL; Fardig, JE; Mackler, NJ; Olson, KB; Pienta, KJ; Redman, BG; Smith, DC | 1 |
| Slovin, SF | 1 |
| Brown, MA; Logothetis, C; Millikan, RE; Pagliaro, LC; Thall, PF; Wen, S; Williams, D | 1 |
| Alimirah, F; Chen, J; Choubey, D; Ho, SM; Panchanathan, R; Zhang, X | 1 |
| Azuma, H; Inamoto, T; Katsuoka, Y; Kiyama, S; Kotake, Y; Nishimura, Y; Sakamoto, T; Segawa, N; Takahara, K; Ubai, T | 1 |
| Akcay, Y; Celasun, B; Ozyilkan, O; Yildirim, Y | 1 |
| Csomor, J; Egyed, M; Egyházi, Z; Fekete, S; Kaszás, I; Kollár, B; Pajor, L; Timár, B | 1 |
| Loprinzi, CL; Trump, DL | 1 |
| Fujita, K; Murayama, T; Sayama, T | 1 |
| Chapman, JD; Elliott, FG; Lakey, WH; Mador, D; McPhee, MS; Meeker, B; Moore, R; Ritchie, B | 1 |
| Fujieda, J; Koyanagi, T; Maru, A; Matsuda, H; Matsuno, T; Minami, S; Morita, H; Nagamori, S; Nonomura, K; Shinohara, N | 1 |
| Appel, C; Cummings, G; Esper, PS; Flaherty, LE; Hussain, M; Pienta, KJ; Redman, B | 1 |
| Akakura, K; Akimoto, S; Masai, M; Ohki, T; Shimazaki, J | 1 |
| Fisher, C; Hayman, R; Hendry, WF; Patel, A | 1 |
| Belldegrun, A; Bonavida, B; Borsellino, N | 1 |
| Kiue, A; Kuwano, M; Nakagawa, M; Nomura, Y; Ogata, J; Tanimura, H; Tasaki, Y | 1 |
| Pienta, KJ; Redman, BG | 1 |
| Kitamura, Y; Komatsubara, S; Sakata, Y; Watanabe, M | 1 |
| Barzan, L; Canzonieri, V; Dal Bo, V; Lo Re, G; Trovò, M; Veronesi, A; Zancanaro, C | 1 |
| Andoh, S; Fujisawa, Y; Hasegawa, Y; Itoh, K; Kotoh, S; Kumazawa, J; Naito, S; Omoto, T; Sagiyama, K; Ueda, T | 1 |
| Borner, MM; Eliot, HM; O'Connor, PM; Schneider, E; Sinha, BK; Yamazaki, H | 1 |
| Berchem, GJ; Bosseler, M; Gelmann, EP; Sugars, LY; Voeller, HJ; Zeitlin, S | 1 |
| Atkins, CD | 1 |
| Roth, BJ | 1 |
| Cummings, GD; Flaherty, LE; Hussain, MH; Pienta, KJ; Redman, BG | 1 |
| Maruoka, M; Miyauchi, T; Nagayama, T; Nishikawa, Y | 1 |
| Koshiba, K; Mukai, N; Rokkaku, S; Soh, S; Uchida, T | 1 |
| Dive, C; Hickman, JA; Morris, ID; Oberhammer, F; Sikorska, M; Wakeling, AE; Walker, PR; Wilson, JW | 1 |
| Ihara, H; Kageyama, S; Kawabe, K; Kurita, Y; Mugiya, S; Nakano, M; Suzuki, K; Ueda, D; Ushiyama, T; Yamaguchi, Y | 1 |
| Dilworth, A; Myers, CE; Sinha, BK; Yamazaki, H | 1 |
| Fukushima, S; Miyamoto, H; Moriyama, M; Nomura, S | 1 |
| Lehr, JE; Pienta, KJ | 1 |
| Lazo, JS; Rusnak, JM | 1 |
| Calmels, TP; Hoyt, DG; Kondo, Y; Lazo, JS; Rusnak, JM; Yalowich, JC | 1 |
| Chrétien, Y; Delanian, S; Dufour, B; Hennequin, C; Housset, M; Maulard-Durdux, C | 1 |
| Hirao, Y; Okajima, E; Ozono, S | 1 |
| Lehr, JE; Naik, H; Pienta, KJ | 1 |
| Fujishiro, Y; Fuse, H; Katayama, T; Muraishi, Y | 1 |
| Flaherty, L; Katato, K; Varterasian, M | 1 |
| Asano, K; Iizuka, N; Ohishi, Y; Onodera, S; Takeuchi, H; Tashiro, K; Wada, T; Yanada, S | 1 |
| Akaza, H; Kawai, K | 1 |
| Chatterjee, D; Pantazis, P; Wyche, JH | 1 |
| Hirao, Y; Kaneko, Y; Momose, H; Okajima, E; Ozono, S; Samma, S; Tsumatani, K; Watanabe, S; Yamada, K | 1 |
| Alken, P; Köhrmann, KU; Kreukler, C; Nebe, T; Siegsmund, MJ; Steidler, A | 1 |
| Colleoni, M; Graiff, C; Manente, P; Nelli, P; Pancheri, F; Sgarbossa, G; Vicario, G | 1 |
| Bandekar, R; Cease, K; Esper, PS; Naik, H; Pienta, KJ; Redman, BG; Smith, DC; Strawderman, M | 1 |
| Hou, Y; Liu, QY; Ribecco, M; Sikorska, M; Walker, PR | 1 |
| Pienta, KJ; Smith, DC | 2 |
| Hamano, K; Maruoka, M; Nagayama, T; Nishikawa, Y | 1 |
| Alivizatos, G; Aravantinos, G; Bamia, C; Constantinidis, C; Deliveliotis, C; Dimopoulos, C; Dimopoulos, MA; Kastriotis, I; Kostakopoulos, A; Panopoulos, C; Pantazopoulos, D; Zervas, A | 1 |
| Chang, C; Uemura, H | 1 |
| Dunn, RL; Pienta, KJ; Smith, DC; Strawderman, MS | 1 |
| Belldegrun, A; Bonavida, B; Borsellino, N; Frost, P; Gárban, H; Mizutani, Y; Ng, CP; Uslu, R | 1 |
| Budman, DR; Calabro, A; Kreis, W | 1 |
| Bonavida, B; Borsellino, N; Ciliberto, G; D'Alessandro, N; Toniatti, C; Travali, S | 1 |
| Aparicio, J; Larrán, J; López, A; Salido, M; Vilches, J | 1 |
| Akaza, H; Tsukamoto, S | 1 |
| Arah, IN; Dixon, SC; Figg, WD; Horti, J | 1 |
| Esper, P; Pienta, KJ; Redman, B; Smith, DC; Strawderman, M | 1 |
| Kim, CJ; Kushima, R; Okada, Y; Seto, A | 1 |
| Appella, E; Connell, T; Gao, C; Moul, JW; Nagaich, AK; Saito, S; Seth, P; Srivastava, S; Zou, Z | 1 |
| Nortier, JW; Shamelian, SO | 1 |
| Cal, C; Gunaydin, G; Omay, SB; Ozyurt, C; Uslu, R | 1 |
| Fuks, Z; Kelly, WK; Lee, H; Leibel, SA; Metz, E; Scher, HI; Schwartz, L; Smart, T; Zelefsky, MJ | 1 |
| Alderson, PO; Cannon, P; Katz, J; Kline, RP; Petrylak, DP; Szabolcs, M; Weisfeldt, ML; Wu, EX | 1 |
| Hashine, K; Karashima, T; Nakatsuzi, H; Sumiyoshi, Y; Yamashita, Y | 1 |
| Bandyopadhyay, S; Goodarzi, G; Gross, SC; Mashimo, T; Pai, SK; Watabe, K; Watabe, M | 1 |
| Brady, HP; Coffey, RN; Fitzpatrick, JM; Gibbons, NB; Watson, RW | 1 |
| López, A; Salido, M; Vilches, J | 1 |
| Greene, DR; Plummer, ER; Roberts, JT | 1 |
| Maruoka, M; Nagayama, T | 1 |
| Olver, IN; Schulze, D; Stephenson, J | 1 |
| Ahmed, K; Davis, AT; Green, JE; Guo, C; Wang, H; Yu, S | 1 |
| Goker, E; Karabulut, B; Omay, SB; Sanli, UA; Sezgin, C; Terzioglu, E; Uslu, R | 1 |
| Ben-Josef, E; Chuba, P; Fontana, J; Han, S; Hussain, M; Mertens, W; Porter, AT | 1 |
| Clark, PE; Clark, SB; Dreicer, R; Klein, EA; Levin, HS; Peereboom, DM | 1 |
| Crawford, ED; Dakhil, SR; Eisenberger, MA; Fisher, EI; Goodwin, JW; Hussain, MH; Jones, JA; Mills, GM; Pienta, KJ | 1 |
| Kamradt, JM; Pienta, KJ | 1 |
| Munshi, HG; Pienta, KJ; Smith, DC | 1 |
| Keller, ET; Smith, PC | 1 |
| Lopez, A; Roomans, GM; Salido, M; Vilches, J | 2 |
| Hudes, GR; Obasaju, C | 1 |
| Brady, HR; Coffey, RN; Fitzpatrick, JM; Hegarty, PK; O'Keane, C; Watson, CL; Watson, RW; Wolohan, L | 1 |
| Aiba, K; Akaza, H; Blackledge, G; Boku, N; Ikeda, T; Isonishi, S; Kato, M; Kawai, K; Mikami, O; Ohashi, Y; Saeki, T; Saijo, N; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T | 1 |
| Asakuma, J; Asano, T; Hayakawa, M; Kuroki, T; Ohba, M; Sumitomo, M | 1 |
| Hayashi, Y; Kawai, N; Kohri, K; Okamoto, T; Sasaki, S; Tozawa, K | 1 |
| Balk, SP; Bubley, GJ; Cheng, S; Lu, ML; Masiello, D | 1 |
| Akaza, H; Hattori, K; Kawai, K; Miyanaga, N; Shimazui, T; Tsukamoto, S; Uchida, K | 1 |
| Aranha, O; Aslam, N; El-Rayes, BF; Grignon, R; Sarkar, FH | 1 |
| Nathan, C; Shen, C | 1 |
| Beckmann, C; Flury, R; Frei, P; Holdener, E; Jungi, WF; Senn, HJ | 1 |
| Moore, SR; Reinberg, Y; Zhang, G | 1 |
| Hirai, M | 2 |
| Crawford, ED; Daneshgari, F; Majeski, SA | 1 |
| Imai, K; Kato, N; Kurita, M; Nakamura, T; Nakazawa, Y; Suzuki, K; Suzuki, T; Yamanaka, H | 1 |
| Akiyama, M; Sumiyoshi, Y; Yokota, K | 1 |
| Frohmüller, H; Heimbach, D; Wirth, M | 1 |
| Kondoh, I; Moriyama, M; Murai, T | 1 |
| Ban, Y; Ishihara, S; Iwata, H; Kanematsu, M; Komeda, H; Kuriyama, M; Oguchi, K; Takeuchi, T; Tanaka, T | 1 |
| Aso, Y; Hirai, M; Kawabe, K; Masuda, H; Nakano, M; Ohta, N; Tajima, A; Ushiyama, T | 1 |
| Hashimura, T; Hida, S; Kanamaru, H; Nishimura, K; Nishio, Y; Oishi, K; Okada, K; Yamauchi, T; Yoshida, O; Yoshiki, T | 1 |
| Maruoka, M; Miyauchi, T; Nagayama, T | 1 |
| Birch, R; Einhorn, LH; Greco, FA; Troner, M; Walther, PJ; Williams, SD | 1 |
| Suzuki, K | 1 |
| Ito, H; Mitsuya, H; Miyake, K; Murase, T; Sobazima, T; Takashi, M | 1 |
| Heston, WD; Hollander, P; Niedzwiecki, D; Scher, HI; Smart, T; Sternberg, C; Watson, RC; Yagoda, A | 1 |
| Aota, Y; Kinjo, T; Mitsuya, H; Murase, T; Shimoji, T | 1 |
19 review(s) available for etoposide and Cancer of Prostate
| Article | Year |
|---|---|
Current and emerging therapies for neuroendocrine prostate cancer.
Topics: Carcinoma, Neuroendocrine; Etoposide; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2022 |
[The non-hormonal treatment of metastatic prostate cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Cisplatin; Denosumab; Docetaxel; Etoposide; Humans; Male; Mitoxantrone; Organometallic Compounds; Organophosphorus Compounds; Osteoporosis; Prostatic Neoplasms; Radiation Protection; Radioisotopes; Radium; RANK Ligand; Strontium; Strontium Radioisotopes; Taxoids | 2013 |
De novo large cell neuroendocrine carcinoma of the prostate gland with pelvic lymph node metastasis: a case report with review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Cisplatin; Cystoscopy; Disease Progression; Etoposide; Fatal Outcome; Humans; Immunohistochemistry; Laparoscopy; Leuprolide; Lymph Node Excision; Lymphatic Metastasis; Male; Meningeal Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Paclitaxel; Pelvis; Prostatic Neoplasms; Robotic Surgical Procedures; Time Factors; Tomography, X-Ray Computed; Transurethral Resection of Prostate; Treatment Outcome | 2014 |
Primary Yolk Sac Tumor of the Prostate: A Case Report and Review of the Literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Disease-Free Survival; Endodermal Sinus Tumor; Etoposide; Humans; Male; Neoplasm Metastasis; Prostatectomy; Prostatic Neoplasms; Recurrence; Robotic Surgical Procedures; Testicular Neoplasms; Treatment Outcome; Vincristine | 2015 |
[Clinical characteristics and treatment of desmoplastic small round cell tumor].
Topics: Abdominal Neoplasms; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophosphamide; Desmoplastic Small Round Cell Tumor; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Liver Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Prostatic Neoplasms; Radiotherapy, Conformal; Surgical Procedures, Operative; Survival Rate; Vincristine; Young Adult | 2010 |
[Chemotherapy for prostate cancers].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Estramustine; Etoposide; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids; Vinblastine | 2002 |
[Intermittent oral hormonal chemotherapy using estramustine phosphate and etoposide for the treatment of hormone-refractory prostate cancer].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Estramustine; Etoposide; Humans; Male; Middle Aged; Prostatic Neoplasms; Survival Rate | 2003 |
Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Estramustine; Etoposide; Gonadotropin-Releasing Hormone; Growth Substances; Humans; Leuprolide; Male; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Orchiectomy; Osteoblasts; Osteoclasts; Paracrine Communication; Peptides, Cyclic; Prospective Studies; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Receptors, Androgen; Salvage Therapy; Somatostatin; Survival Analysis; Triptorelin Pamoate | 2006 |
New treatment strategies for hormone refractory prostate cancer.
Topics: Estramustine; Etoposide; Humans; Male; Prostatic Neoplasms; Suramin; Vinblastine | 1995 |
[Treatment for hormone-refractory or relapsing prostatic cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prostatic Neoplasms; Survival Rate; Vinblastine | 1996 |
[The role of etoposide therapy in urogenital cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Etoposide; Female; Humans; Kidney Neoplasms; Male; Prostatic Neoplasms; Urinary Bladder Neoplasms; Vinblastine | 1996 |
[Progress in oral anti-cancer drug therapy for urological cancer].
Topics: Administration, Oral; Androgen Antagonists; Antineoplastic Agents, Hormonal; Drug Administration Schedule; Drug Combinations; Estramustine; Etoposide; Female; Flutamide; Humans; Kidney Neoplasms; Male; Prostatic Neoplasms; Tegafur; Uracil; Urinary Bladder Neoplasms | 1999 |
Paclitaxel in the treatment of hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Estramustine; Etoposide; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms | 1999 |
[Treatment of hormone-refractory prostate cancer with etoposide (Vp16)].
Topics: Aged; Antineoplastic Agents, Phytogenic; Etoposide; Humans; Male; Prostatic Neoplasms | 2000 |
Etoposide in prostate cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Cyclophosphamide; Estramustine; Etoposide; Humans; Male; Prostatic Neoplasms | 2000 |
Paclitaxel and docetaxel in prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estramustine; Etoposide; Genes, bcl-2; Humans; Hydrocortisone; Male; Microtubules; Mitosis; Mitoxantrone; Multicenter Studies as Topic; Neoplasm Proteins; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Palliative Care; Prostatic Neoplasms; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Survival Analysis; Taxoids; Treatment Outcome; Tubulin | 2001 |
[Chemotherapy and radiotherapy for urological cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Kidney Neoplasms; Male; Methotrexate; Prostatic Neoplasms; Testicular Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2002 |
Small cell carcinoma of prostate: effectiveness of hormonal versus chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chlorotrianisene; Cyclophosphamide; Diethylstilbestrol; Doxorubicin; Etoposide; Humans; Leuprolide; Male; Middle Aged; Prostatectomy; Prostatic Neoplasms | 1992 |
[New combination chemotherapy in refractory rhabdomyosarcoma of the prostate: a case report and review of the literature].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Etoposide; Humans; Male; Neoplasm Recurrence, Local; Peplomycin; Peptichemio; Prednisone; Prostatic Neoplasms; Rhabdomyosarcoma; Vincristine | 1987 |
42 trial(s) available for etoposide and Cancer of Prostate
| Article | Year |
|---|---|
Oral etoposide and oral prednisone for the treatment of castration resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Etoposide; Humans; Male; Middle Aged; Prednisone; Prostatic Neoplasms | 2014 |
A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Early Termination of Clinical Trials; Estramustine; Etoposide; Humans; Male; Middle Aged; Neoplasm Grading; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors | 2015 |
Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-ris
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Estramustine; Etoposide; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Paclitaxel; Prostatic Neoplasms; Thromboembolism | 2009 |
Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Etoposide; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 2009 |
Oral chemotherapy in hormone-refractory prostate carcinoma patients unwilling to be admitted to hospital.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Estramustine; Etoposide; Hospitalization; Humans; Male; Middle Aged; Patient Compliance; Prostatic Neoplasms | 2009 |
Combination therapy with VP16 and ethinylestradiol for hormone-refractory prostate cancer: good response with tolerability.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Ethinyl Estradiol; Etoposide; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life | 2010 |
Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Estramustine; Etoposide; Humans; Injections, Intravenous; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Risk Factors | 2011 |
Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Differentiation; Chromogranin A; Disease-Free Survival; Etoposide; Humans; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Neuroendocrine Cells; Orchiectomy; Prospective Studies; Prostatic Neoplasms | 2011 |
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Small Cell; Cisplatin; Disease Progression; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Prostatic Neoplasms; Survival Analysis; Treatment Outcome | 2002 |
Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Resistance, Neoplasm; Estramustine; Etoposide; Humans; Ketoconazole; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Rate; Treatment Outcome | 2003 |
Bi-weekly epirubicin, etoposide and low-dose dexamethasone for hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dexamethasone; Drug Administration Schedule; Epirubicin; Etoposide; Hormone Antagonists; Humans; Male; Middle Aged; Pain; Prostate-Specific Antigen; Prostatic Neoplasms; Soft Tissue Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Estramustine; Etoposide; Humans; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Rats; Survival Rate; Treatment Outcome | 2003 |
Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Estramustine; Etoposide; Fatigue; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Prostatic Neoplasms; Sepsis; Survival Analysis; Treatment Outcome | 2003 |
Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Dexamethasone; Diabetes Mellitus; Disease-Free Survival; Estramustine; Etoposide; Gastrointestinal Diseases; Gonadotropin-Releasing Hormone; Hematologic Diseases; Humans; Life Tables; Male; Middle Aged; Orchiectomy; Peptides, Cyclic; Prostatic Neoplasms; Somatostatin; Survival Analysis; Treatment Outcome; Triptorelin Pamoate | 2004 |
Phase II trial of estramustine and etoposide in androgen-sensitive metastatic prostate carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Etoposide; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Survival Rate | 2004 |
Phase II study of prolonged ambulatory infusion carboplatin and oral etoposide for patients progressing through hormonal therapy for prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etoposide; Follow-Up Studies; Humans; Infusion Pumps; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; Treatment Outcome | 2005 |
Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Estramustine; Etoposide; Feasibility Studies; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Treatment Outcome | 2007 |
Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
Topics: Aged; Algorithms; Androgens; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Confidence Intervals; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Estramustine; Etoposide; Humans; Ketoconazole; Logistic Models; Male; Middle Aged; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Research Design; Survival Analysis; Treatment Outcome; Vinblastine; Vincristine | 2007 |
[Clinicopathological evaluation of etoposide or estramustine phosphate in castrated patients with advanced prostatic cancer].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Drug Administration Schedule; Estramustine; Etoposide; Humans; Male; Orchiectomy; Prostatic Neoplasms; Survival Rate | 1995 |
Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Estramustine; Etoposide; Follow-Up Studies; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Remission Induction; Survival Rate | 1994 |
Chemotherapy for endocrine-therapy-refractory prostate cancer.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Doxorubicin; Estrogens; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Orchiectomy; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Vincristine | 1994 |
Treatment of advanced hormone-refractory prostate carcinoma with a combination of etoposide, pirarubicin and cisplatin.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; Drug Resistance; Estrogens; Etoposide; Gonadotropin-Releasing Hormone; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Treatment Outcome | 1995 |
[Results of combination chemotherapy with etoposide, ifosfamide, peplomycin for advanced prostatic cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Diethylstilbestrol; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Male; Middle Aged; Orchiectomy; Peplomycin; Prognosis; Prostatic Neoplasms; Survival Rate | 1993 |
[Clinical trial of the systemic chemotherapy for advanced prostatic cancer patients].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Etoposide; Humans; Male; Methotrexate; Middle Aged; Prognosis; Prostatic Neoplasms | 1993 |
Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Humans; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms; Treatment Outcome | 1996 |
[Clinical study of testicular cancer].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Etoposide; Germinoma; Humans; Ifosfamide; Lymph Node Excision; Male; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Survival Rate; Vinblastine | 1996 |
Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Drug Administration Schedule; Estramustine; Etoposide; Humans; Male; Middle Aged; Neutropenia; Prostate-Specific Antigen; Prostatic Neoplasms; Remission Induction; Vinblastine; Vinorelbine | 1997 |
A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer.
Topics: Administration, Oral; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Etoposide; Humans; Male; Prostatic Neoplasms; Survival Rate | 1997 |
Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Alopecia; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; DNA Replication; DNA, Neoplasm; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Estramustine; Etoposide; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Microtubules; Nuclear Matrix; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Rats; Remission Induction; Tumor Cells, Cultured | 1997 |
Oral estramustine and oral etoposide for hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Etoposide; Humans; Male; Middle Aged; Prostatic Neoplasms; Survival Rate | 1997 |
Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Etoposide; Hemoglobins; Humans; Male; Middle Aged; Multivariate Analysis; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Regression Analysis; Survival Rate | 1998 |
Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Drug Resistance, Neoplasm; Estramustine; Etoposide; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Quality of Life; Soft Tissue Neoplasms; Survival Rate; Treatment Outcome | 1999 |
Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Estramustine; Etoposide; Gastrointestinal Diseases; Humans; Injections, Intravenous; Male; Male Urogenital Diseases; Neoadjuvant Therapy; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Conformal; Risk Factors; Treatment Outcome; Vinblastine; Vindesine | 2000 |
Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Etoposide; Humans; Male; Middle Aged; Prostatic Neoplasms | 2000 |
A phase I study of prolonged ambulatory infusion carboplatin with oral etoposide showing activity in prostate cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Drug Therapy, Combination; Etoposide; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Pain; Prostatic Neoplasms; Treatment Outcome | 2000 |
Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Estramustine; Etoposide; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Treatment Outcome | 2001 |
A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407).
Topics: Administration, Oral; Aged; Aged, 80 and over; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Estramustine; Etoposide; Humans; Male; Middle Aged; Nausea; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome; Venous Thrombosis | 2001 |
Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma: a phase II trial of oral estramustine and oral etoposide.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Disease-Free Survival; Estramustine; Etoposide; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 2001 |
[Basic and clinical studies of local hyperthermia for prostatic cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Animals; Bleomycin; Cisplatin; Combined Modality Therapy; Dogs; Etoposide; Humans; Hyperthermia, Induced; Male; Middle Aged; Peplomycin; Prostate; Prostatic Neoplasms | 1992 |
Etoposide in the treatment of hormone-refractory advanced carcinoma of the prostate.
Topics: Administration, Oral; Androgens; Etoposide; Humans; Male; Prostatic Neoplasms; Treatment Outcome | 1992 |
[Chemotherapy in metastasizing prostate carcinoma].
Topics: Aged; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Male; Methotrexate; Prostatic Neoplasms; Survival Analysis | 1991 |
Phase II study of etoposide for carcinoma of the prostate.
Topics: Blood Cell Count; Clinical Trials as Topic; Drug Evaluation; Etoposide; Hematologic Diseases; Humans; Male; Podophyllotoxin; Prostatic Neoplasms | 1986 |
162 other study(ies) available for etoposide and Cancer of Prostate
| Article | Year |
|---|---|
4β-amidotriazole linked podophyllotoxin congeners: DNA topoisomerase-IIα inhibition and potential anticancer agents for prostate cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Humans; Male; Membrane Potential, Mitochondrial; Molecular Docking Simulation; Molecular Structure; Podophyllotoxin; Prostatic Neoplasms; Reactive Oxygen Species; Structure-Activity Relationship; Topoisomerase II Inhibitors; Triazoles; Tumor Cells, Cultured | 2018 |
Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways.
Topics: Animals; Bridged-Ring Compounds; Cell Line, Tumor; Disease Models, Animal; DNA Repair; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Etoposide; Gene Expression; Humans; Immunohistochemistry; Male; Mice; Prostatic Neoplasms; Signal Transduction; Taxoids; Topoisomerase II Inhibitors; Xenograft Model Antitumor Assays | 2021 |
Apoptosis as Driver of Therapy-Induced Cancer Repopulation and Acquired Cell-Resistance (CRAC): A Simple In Vitro Model of Phoenix Rising in Prostate Cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cellular Reprogramming; Drug Resistance, Neoplasm; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Male; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Tumor Cells, Cultured | 2022 |
Cytotoxic Action of Palladium-Based Compound on Prostate Stem Cells, Primary Prostate Epithelial Cells, Prostate Epithelial Cells, and Prostate Cell Lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Epithelial Cells; Etoposide; Humans; Male; Palladium; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Stem Cells | 2022 |
Treatment outcome after sequential chemotherapy with cisplatin-etoposide, amrubicin and nogitecan in patients with treatment-related pure small-cell neuroendocrine prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2023 |
Optimization of Fluence Map for CyberKnife Raster Scanning Intensity Modulated Radiotherapy.
Topics: Carmustine; Etoposide; Humans; Male; Prostatic Neoplasms; Radiosurgery; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Rectum | 2023 |
Stereotactic beam radiotherapy for prostate cancer: is less, more?
Topics: Dose Fractionation, Radiation; Etoposide; Humans; Male; Prostatic Neoplasms; Radiosurgery; Radiotherapy, Intensity-Modulated | 2019 |
SPOP is essential for DNA-protein cross-link repair in prostate cancer cells: SPOP-dependent removal of topoisomerase 2A from the topoisomerase 2A-DNA cleavage complex.
Topics: Cell Death; Cell Nucleus; DNA Cleavage; DNA Replication; DNA Topoisomerases, Type II; DNA, Neoplasm; Etoposide; Histones; Humans; Hydroxyurea; Male; Models, Biological; Mutation; Nuclear Proteins; Poly-ADP-Ribose Binding Proteins; Prostatic Neoplasms; Receptors, Androgen; Repressor Proteins; Topoisomerase Inhibitors | 2020 |
Prostate cancer cells modulate the differentiation of THP-1 cells in response to etoposide and TLR agonists treatments.
Topics: Cell Differentiation; Coculture Techniques; Etoposide; Humans; Male; PC-3 Cells; Prostatic Neoplasms; THP-1 Cells; Toll-Like Receptor 4; Toll-Like Receptor 8; Tumor-Associated Macrophages | 2020 |
Etoposide Loaded SPION-PNIPAM Nanoparticles Improve the in vitro Therapeutic Outcome on Metastatic Prostate Cancer Cells via Enhanced Apoptosis.
Topics: Acrylic Resins; Apoptosis; Biocompatible Materials; Cell Line, Tumor; Drug Carriers; Etoposide; Ferric Compounds; Humans; Magnetic Iron Oxide Nanoparticles; Male; Prostatic Neoplasms | 2020 |
DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Chromones; DNA Damage; DNA-Activated Protein Kinase; Docetaxel; Drug Resistance, Neoplasm; Etoposide; Humans; Male; Morpholines; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyridazines; Quinazolines; Taxoids | 2021 |
[Neuroendocrine prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chromogranin A; Cisplatin; Etoposide; Humans; Male; Neoplasms, Second Primary; Neuroendocrine Tumors; Phosphopyruvate Hydratase; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Survival Rate | 2017 |
Caspase-dependent apoptosis induced by two synthetic halogenated flavanones, 3',7-dichloroflavanone and 3',6-dichloroflavanone, on human breast and prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Survival; Etoposide; Female; Flavanones; Humans; Male; Poly (ADP-Ribose) Polymerase-1; Prostatic Neoplasms | 2018 |
Successful treatment of concomitant metastatic prostate cancer and B-cell non-Hodgkin's lymphoma with R-EPOCH chemotherapy regimen and antiandrogen therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasms, Multiple Primary; Positron-Emission Tomography; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Rituximab; Vincristine | 2018 |
Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Small Cell; Cisplatin; Databases, Factual; DNA Repair; Etoposide; Gene Expression Profiling; Genes, Tumor Suppressor; Genetic Predisposition to Disease; Genomic Instability; Humans; Male; Middle Aged; Neoplasms, Complex and Mixed; Phenotype; Prostatic Neoplasms; Retrospective Studies; Time Factors; Treatment Outcome | 2018 |
Primary large cell neuroendocrine carcinoma of the prostate in a hormone naive patient: A case report from Taiwan.
Topics: Aged; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Humans; Male; Prostate; Prostatic Neoplasms; Taiwan; Transurethral Resection of Prostate | 2018 |
Etoposide encased folic acid adorned mesoporous silica nanoparticles as potent nanovehicles for enhanced prostate cancer therapy: synthesis, characterization, cellular uptake and biodistribution.
Topics: Cell Line, Tumor; Drug Carriers; Etoposide; Folic Acid; Humans; Male; Nanoparticles; Prostatic Neoplasms; Silicon Dioxide | 2018 |
Increased chemosensitivity via targeting testicular nuclear receptor 4 (TR4)-Oct4-interleukin 1 receptor antagonist (IL1Ra) axis in prostate cancer CD133+ stem/progenitor cells to battle prostate cancer.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glycoproteins; Humans; Interleukin 1 Receptor Antagonist Protein; Male; Neoplastic Stem Cells; Octamer Transcription Factor-3; Peptides; Prostatic Neoplasms; Receptors, Steroid; Receptors, Thyroid Hormone; Taxoids | 2013 |
DNA damage response (DDR) via NKX3.1 expression in prostate cells.
Topics: Acid Anhydride Hydrolases; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Cycle; Cell Line, Tumor; Cyclin D1; DNA Damage; DNA Repair; DNA Repair Enzymes; DNA-Activated Protein Kinase; DNA-Binding Proteins; Doxorubicin; Etoposide; Histones; Homeodomain Proteins; Humans; Hydrogen Peroxide; Irinotecan; Male; Metribolone; Mutagens; Phosphorylation; Prostatic Neoplasms; Protein Processing, Post-Translational; Testosterone Congeners; Transcription Factors | 2014 |
Prostate cancer stem-like cells proliferate slowly and resist etoposide-induced cytotoxicity via enhancing DNA damage response.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Proliferation; Colony-Forming Units Assay; DNA Damage; Etoposide; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Prostatic Neoplasms; Tumor Cells, Cultured | 2014 |
Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Disease-Free Survival; DNA Topoisomerases, Type II; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Indoles; Male; Mice, Inbred C57BL; Poly-ADP-Ribose Binding Proteins; Polycomb Repressive Complex 2; Precision Medicine; Predictive Value of Tests; Prostatic Neoplasms; Pyridones; RNA, Messenger; Time Factors; Topoisomerase II Inhibitors; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
Induction of morphological changes in death-induced cancer cells monitored by holographic microscopy.
Topics: Animals; Cell Death; Cell Line; Cell Proliferation; Cell Size; Cell Survival; Etoposide; Fibroblasts; Holography; Humans; Male; Mice; Microscopy; Prostatic Neoplasms | 2015 |
BMX Negatively Regulates BAK Function, Thereby Increasing Apoptotic Resistance to Chemotherapeutic Drugs.
Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Male; Phosphorylation; Prostatic Neoplasms; Protein Processing, Post-Translational; Protein Tyrosine Phosphatases, Non-Receptor; Protein-Tyrosine Kinases | 2015 |
Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.
Topics: Animals; Binding Sites; Cell Line, Tumor; Cell Transformation, Neoplastic; Checkpoint Kinase 1; Conserved Sequence; Disease Progression; DNA Damage; DNA-Binding Proteins; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Genotype; Humans; Male; Mice; Mice, Knockout; Promoter Regions, Genetic; Prostatic Neoplasms; Protein Binding; Protein Kinases; Proto-Oncogene Proteins c-ets; PTEN Phosphohydrolase; Trans-Activators; Transcription Factors; Transcription, Genetic; Transcriptional Regulator ERG; Tumor Suppressor Protein p53 | 2015 |
Nanoemulsion based concomitant delivery of curcumin and etoposide: impact on cross talk between prostate cancer cells and osteoblast during metastasis.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cell Communication; Cell Line, Tumor; Curcumin; Drug Combinations; Emulsions; Etoposide; Humans; Male; Mice; Nanocapsules; Osteoblasts; Prostatic Neoplasms; Rats, Sprague-Dawley; Treatment Outcome | 2014 |
SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression.
Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Movement; Cullin Proteins; Disease Progression; Etoposide; HEK293 Cells; Humans; Male; Molecular Sequence Data; Neoplasm Invasiveness; Nuclear Proteins; Prostatic Neoplasms; Protein Interaction Domains and Motifs; Proteolysis; Repressor Proteins; Trans-Activators; Transcriptional Regulator ERG; Tumor Suppressor Proteins; Ubiquitination | 2015 |
Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Cells, Cultured; DNA Breaks, Double-Stranded; DNA Repair; Etoposide; Exome; Family Health; Genetic Predisposition to Disease; Histones; Humans; INDEL Mutation; Male; Middle Aged; Mutation; Polymorphism, Single Nucleotide; Prostatic Neoplasms; Risk Assessment; Risk Factors; Sequence Analysis, DNA; T-Lymphocytes | 2015 |
Superoxide Dismutase 1 Regulation of CXCR4-Mediated Signaling in Prostate Cancer Cells is Dependent on Cellular Oxidative State.
Topics: Apoptosis; Cell Line, Tumor; Chemokine CXCL12; Etoposide; Humans; Male; Oxidative Stress; Prostatic Neoplasms; Receptors, CXCR4; Signal Transduction; Superoxide Dismutase; Superoxide Dismutase-1 | 2015 |
[SMALL CELL CARCINOMA OF THE PROSTATE: A CASE REPORT OF RELATIVE LONG-TERM SURVIVAL].
Topics: Aged; Anthracyclines; Antineoplastic Agents; Carboplatin; Carcinoma, Small Cell; Etoposide; Fatal Outcome; Humans; Lymphatic Metastasis; Male; Multimodal Imaging; Positron-Emission Tomography; Prostatic Neoplasms; Time Factors; Tomography, X-Ray Computed | 2015 |
Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Bleomycin; Cisplatin; Clinical Trials, Phase II as Topic; Etoposide; Female; Humans; Male; Multicenter Studies as Topic; Neoplasms, Germ Cell and Embryonal; New Zealand; Prostatic Neoplasms; Time Factors; Treatment Outcome; Urogenital Neoplasms | 2016 |
[Etoposide and Carboplatin Effective for Treatment of Small Cell Carcinoma of Prostate : A Report of Two Cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Humans; Male; Prostatic Neoplasms; Tomography, X-Ray Computed | 2016 |
Sensitivity of human prostate cancer cells to chemotherapeutic drugs depends on EndoG expression regulated by promoter methylation.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; CpG Islands; DNA Methylation; Endodeoxyribonucleases; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Male; Promoter Regions, Genetic; Prostatic Neoplasms | 2008 |
Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Kallikreins; Male; Mitoxantrone; Necrosis; Prostatic Neoplasms; RNA, Messenger; Serine Endopeptidases; Time Factors | 2009 |
Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferation.
Topics: Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Cell Line, Tumor; Cell Proliferation; Cell Survival; Data Interpretation, Statistical; Etoposide; Gene Expression; Gene Knockdown Techniques; Humans; Inhibitor of Apoptosis Proteins; Male; Peptide Hydrolases; Prostatic Neoplasms; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Tunicamycin; Ubiquitin-Protein Ligases; X-Linked Inhibitor of Apoptosis Protein | 2009 |
The effect of a novel botanical agent TBS-101 on invasive prostate cancer in animal models.
Topics: Animals; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Chamomile; Dose-Response Relationship, Drug; Etoposide; Ganoderma; Humans; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Panax; Phytotherapy; Plant Extracts; Prostatic Neoplasms; Vaccinium macrocarpon; Vitis; Xenograft Model Antitumor Assays | 2009 |
Etoposide induces growth arrest and disrupts androgen receptor signaling in prostate cancer cells.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Cytoplasm; Dose-Response Relationship, Drug; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Male; Microscopy, Confocal; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Subcellular Fractions | 2010 |
Primary seminoma of the prostate.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bleomycin; Cisplatin; Etoposide; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Middle Aged; Prostatic Neoplasms; Seminoma | 2009 |
Targeting protein kinase C (PKC) and telomerase by phenethyl isothiocyanate (PEITC) sensitizes PC-3 cells towards chemotherapeutic drug-induced apoptosis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Caspases; Cell Line, Tumor; Cytochromes c; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Isothiocyanates; Male; Prostatic Neoplasms; Protein Kinase C; Telomerase | 2009 |
CCR9 mediates PI3K/AKT-dependent antiapoptotic signals in prostate cancer cells and inhibition of CCR9-CCL25 interaction enhances the cytotoxic effects of etoposide.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Chemokines, CC; Disease Progression; Enzyme Activation; Etoposide; Humans; Male; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Receptors, CCR; Signal Transduction | 2010 |
Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Antagonism; Drug Synergism; Drug Therapy, Combination; Etoposide; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Male; Mitoxantrone; Neoplasm Metastasis; Piperazines; Prostatic Neoplasms; Pyrimidines; Vinblastine | 2011 |
68Ga-DOTATOC-PET/CT detects neuroendocrine differentiation of prostate cancer metastases.
Topics: Anilides; Antineoplastic Agents; Cell Differentiation; Cisplatin; Etoposide; Humans; Male; Middle Aged; Nitriles; Octreotide; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Tomography, X-Ray Computed; Tosyl Compounds | 2009 |
MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Daunorubicin; DNA Primers; Drug Resistance, Neoplasm; Etoposide; Humans; Male; MicroRNAs; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sirtuin 1; Tumor Suppressor Protein p53 | 2010 |
Involvement of riboflavin kinase expression in cellular sensitivity against cisplatin.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Diamide; Drug Resistance, Neoplasm; Etoposide; Flavins; Glutathione; Humans; Hydrogen Peroxide; Male; Oxidants; Oxidative Stress; Phosphotransferases (Alcohol Group Acceptor); Prostatic Neoplasms; Recombinant Proteins | 2011 |
Complete remission in a patient with metastatic mixed adenocarcinoma/extrapulmonary small cell carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Bone Neoplasms; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Prostatic Neoplasms; Remission Induction | 2011 |
Induction of DNA damage and caspase-independent programmed cell death by vitamin E.
Topics: Apoptosis; Caspase 3; Caspases; Cell Line, Tumor; DNA Damage; Drug Screening Assays, Antitumor; Etoposide; Humans; Isomerism; Male; Poly(ADP-ribose) Polymerases; Polyethylene Glycols; Prostatic Neoplasms; Tocotrienols; Vitamin E | 2012 |
Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Cyclin B1; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Drug Synergism; Etoposide; Flow Cytometry; Fluorouracil; Humans; Inhibitor of Apoptosis Proteins; Male; Prostatic Neoplasms; Quercetin; Survivin; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 2012 |
Reformulation of etoposide with solubility-enhancing rubusoside.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Colonic Neoplasms; Dimethyl Sulfoxide; Diterpenes, Kaurane; Drug Stability; Drug Storage; Etoposide; Excipients; Female; Glucosides; Humans; Light; Male; Microscopy, Electron, Transmission; Nanoparticles; Particle Size; Prostatic Neoplasms; Scattering, Radiation; Solubility; Temperature | 2012 |
ATM and LKB1 dependent activation of AMPK sensitizes cancer cells to etoposide-induced apoptosis.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Antineoplastic Agents, Phytogenic; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; DNA-Binding Proteins; Enzyme Activation; Etoposide; Humans; Male; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Tumor Suppressor Proteins | 2013 |
Characterization of the low pH/low nutrient-resistant LNCaP cell subline LNCaP-F10.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Tumor; Cell Proliferation; Death-Associated Protein Kinases; DNA Fragmentation; Docetaxel; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Hydrogen-Ion Concentration; Inhibitor of Apoptosis Proteins; Male; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Survivin; Taxoids; Transplantation, Heterologous | 2012 |
Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Caspases; Cell Survival; Cisplatin; Combined Modality Therapy; Doxorubicin; Drug Synergism; Etoposide; Humans; Male; Membrane Glycoproteins; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Tumor Stem Cell Assay | 2002 |
Drug resistance in prostate cancer cell lines is influenced by androgen dependence and p53 status.
Topics: Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Estramustine; Etoposide; Gene Expression Regulation; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vinblastine | 2002 |
Phosphorylation of Fas-associated death domain contributes to enhancement of etoposide-induced apoptosis in prostate cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; bcl-X Protein; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 3; Caspases; Cell Cycle; Enzyme Activation; Etoposide; Fas-Associated Death Domain Protein; Humans; Intracellular Signaling Peptides and Proteins; JNK Mitogen-Activated Protein Kinases; Male; Mitogen-Activated Protein Kinases; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Serine; Tumor Cells, Cultured | 2002 |
Gene therapy for prostate cancer by targeting poly(ADP-ribose) polymerase.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; DNA Damage; DNA-Binding Proteins; DNA, Neoplasm; Etoposide; Genetic Therapy; Humans; Male; Metribolone; Neoplasms, Hormone-Dependent; Plasmids; Poly(ADP-ribose) Polymerases; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Structure, Tertiary; Testosterone Congeners; Transfection; Tumor Cells, Cultured | 2002 |
[Small cell carcinoma of the prostate: a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Fatal Outcome; Humans; Male; Prostatic Neoplasms; Radiotherapy, Adjuvant | 2002 |
c-Jun NH2-terminal kinase-dependent Fas activation contributes to etoposide-induced apoptosis in p53-mutated prostate cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Arabidopsis Proteins; Blotting, Western; Caspases; DNA Fragmentation; Etoposide; fas Receptor; Fatty Acid Desaturases; Flow Cytometry; Genes, p53; Humans; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase 7; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Mutation; Prostatic Neoplasms; Proteins; Transfection; Tumor Cells, Cultured | 2003 |
Association of mitochondrial calpain activation with increased expression and autolysis of calpain small subunit in an early stage of apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Autolysis; Breast Neoplasms; Calpain; Cytochrome c Group; Enzyme Activation; Enzyme Inhibitors; Etoposide; Female; Humans; Imidazoles; Jurkat Cells; Male; Mitochondria; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Prostatic Neoplasms; Protein Subunits; Tamoxifen; Tumor Cells, Cultured | 2003 |
Prostate carcinoma presenting as multiple pulmonary nodules in an asymptomatic patient with a history of testicular nonseminomatous germ cell tumor.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Etoposide; Flutamide; Humans; Leuprolide; Lung Neoplasms; Male; Neoplasms, Germ Cell and Embryonal; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Orchiectomy; Postoperative Complications; Prostatic Neoplasms; Radiography; Testicular Neoplasms | 2003 |
Combination chemotherapy for hormone-refractory prostate carcinoma: progress and pitfalls.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estramustine; Etoposide; Humans; Male; Paclitaxel; Prostatic Neoplasms; Treatment Outcome | 2003 |
The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA, Neoplasm; Etoposide; Humans; Male; Nuclear Proteins; Oncogene Proteins, Viral; Papillomaviridae; Peptide Hydrolases; Phosphorylation; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Pyrazines; Subcellular Fractions; Transcriptional Activation; Transfection; Tumor Suppressor Protein p53 | 2003 |
A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cells.
Topics: Adenoviridae; Apoptosis; Blotting, Western; Cell Line, Tumor; Down-Regulation; Etoposide; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, p53; Genetic Vectors; Humans; Male; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Tumor Suppressor Protein p53; Up-Regulation | 2004 |
Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Estramustine; Etoposide; Humans; Male; Middle Aged; Prostatic Neoplasms; Remission Induction | 2002 |
Chemosensitization of androgen-independent prostate cancer with neutral endopeptidase.
Topics: Androgens; Annexin A5; Antineoplastic Agents, Phytogenic; Apoptosis; Cells, Cultured; Drug Resistance, Neoplasm; Epithelial Cells; Etoposide; Humans; Male; Mitochondria; Neoplasms, Hormone-Dependent; Neprilysin; Organophosphonates; Phenylalanine; Prostate; Prostatic Neoplasms; Protein Kinase C; Protein Kinase C-delta; Recombinant Proteins | 2004 |
IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; bcl-X Protein; Breast Neoplasms; Camptothecin; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Cell Survival; Etoposide; fas Receptor; Female; Humans; Interleukin-4; Intracellular Signaling Peptides and Proteins; Male; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Up-Regulation | 2004 |
Secondary leukemias in refractory germ cell tumor patients undergoing autologous stem-cell transplantation using high-dose etoposide.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Carboplatin; Combined Modality Therapy; Etoposide; Germinoma; Humans; Incidence; Indiana; Leukemia; Male; Middle Aged; Prostatic Neoplasms; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Transplantation, Autologous | 2004 |
Changes in elemental concentrations in LNCaP cells are associated with a protective effect of neuropeptides on etoposide-induced apoptosis.
Topics: Apoptosis; Cell Division; Cell Line, Tumor; Cell Shape; Cell Survival; Electron Probe Microanalysis; Etoposide; Humans; Kinetics; Male; Microscopy, Electron, Scanning; Neuropeptides; Potassium; Prostatic Neoplasms; Protective Agents; Sodium | 2004 |
Metastatic Merkel cell tumor to the prostate and bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Merkel Cell; Combined Modality Therapy; Etoposide; Facial Neoplasms; Fatal Outcome; Humans; Kidney Neoplasms; Liver Neoplasms; Lymphatic Metastasis; Male; Palliative Care; Prostatic Neoplasms; Radiotherapy, Adjuvant; Spinal Neoplasms; Transurethral Resection of Prostate; Urethral Obstruction; Urinary Bladder Neoplasms | 2004 |
Saposin C promotes survival and prevents apoptosis via PI3K/Akt-dependent pathway in prostate cancer cells.
Topics: Apoptosis; Caspases; Cell Line, Tumor; Cell Survival; Chromones; Culture Media, Serum-Free; Enzyme Activation; Etoposide; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Mitogen-Activated Protein Kinases; Morpholines; Neoplasm Proteins; Pertussis Toxin; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Saposins; Signal Transduction | 2004 |
In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cyclophosphamide; Docetaxel; Drug Synergism; Estramustine; Etoposide; Humans; Imatinib Mesylate; Immunohistochemistry; In Vitro Techniques; Male; Piperazines; Prostatic Neoplasms; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Taxoids | 2005 |
Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells.
Topics: Androgens; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspases; Drug Therapy, Combination; Enzyme Activation; Etoposide; Humans; JNK Mitogen-Activated Protein Kinases; Male; Organoselenium Compounds; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Tumor Cells, Cultured | 2005 |
Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo.
Topics: Adenoviridae; Animals; Antisense Elements (Genetics); Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Etoposide; Humans; Inhibitor of Apoptosis Proteins; Male; Mice; Mice, Inbred BALB C; Microtubule-Associated Proteins; Neoplasm Proteins; Neoplasm Transplantation; Prostatic Neoplasms; Survivin; Taxoids; Transplantation, Heterologous | 2005 |
Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells.
Topics: Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Bisbenzimidazole; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Fluorouracil; Humans; Immunoblotting; Inhibitor of Apoptosis Proteins; Male; Microtubule-Associated Proteins; Neoplasm Proteins; Neuronal Apoptosis-Inhibitory Protein; Paclitaxel; Phenotype; Prostatic Neoplasms; Survivin; Taxoids; Tetrazolium Salts; Time Factors; Ubiquitin-Protein Ligases; X-Linked Inhibitor of Apoptosis Protein | 2005 |
Is it reasonable to consider second-line chemotherapy in patients with hormone-refractory prostate cancer?
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Hormones; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Thrombocytopenia; Time Factors; Treatment Outcome | 2005 |
Adrenomedullin prevents apoptosis in prostate cancer cells.
Topics: Adrenomedullin; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cell Proliferation; Drug Resistance, Neoplasm; Etoposide; Humans; Male; Mitogen-Activated Protein Kinase 3; Peptides; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Transfection; Tumor Cells, Cultured | 2006 |
Androgen receptor activity is inhibited in response to genotoxic agents in a p53-independent manner.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Chromatin Immunoprecipitation; Cisplatin; Dihydrotestosterone; Etoposide; Humans; Ligands; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Receptors, Androgen; Subcellular Fractions; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2006 |
[Chemo-endocrine therapy for newly diagnosed stage D2 prostate cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prostatic Neoplasms; Retrospective Studies; Survival Analysis | 2005 |
Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors.
Topics: Antibodies; Apoptosis; Apoptosis Regulatory Proteins; Caspases; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; fas Receptor; Humans; Ligands; Male; Membrane Glycoproteins; Prostatic Neoplasms; Receptors, Tumor Necrosis Factor; Staurosporine; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2006 |
Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer.
Topics: Apoptosis; bcl-Associated Death Protein; Caspase 3; Caspase Inhibitors; Caspases; Cell Line, Tumor; Cell Nucleus; Cisplatin; Cytochromes c; Enzyme Activation; Etoposide; Galectin 3; Humans; Male; Mitochondria; Prostatic Neoplasms; Transfection | 2006 |
Inhibiting myosin light chain kinase retards the growth of mammary and prostate cancer cells.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Azepines; Cell Division; Chemotherapy, Adjuvant; Etoposide; Humans; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Myosin-Light-Chain Kinase; Naphthalenes; Prostatic Neoplasms; Random Allocation; Rats | 2006 |
Primary immature teratoma of the prostate with angiosarcoma component: its unusual response to chemotherapy.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bleomycin; Cisplatin; Diagnosis, Differential; Etoposide; Hemangiosarcoma; Humans; Male; Neoplasms, Multiple Primary; Prostatic Neoplasms; Teratoma; Tomography, X-Ray Computed | 2006 |
Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Estramustine; Etoposide; Humans; Injections, Intraperitoneal; Male; Neoplasm Invasiveness; Neoplasm Transplantation; Piperazines; Prostatic Neoplasms; Pyrimidines; Rats; Time Factors; Tissue Inhibitor of Metalloproteinases | 2007 |
Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Proliferation; Cells, Cultured; Ceramides; Cytochromes c; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Etoposide; Flow Cytometry; Gefitinib; Humans; Immunoenzyme Techniques; Male; Membrane Potential, Mitochondrial; Neoplasms, Hormone-Dependent; Prostate; Prostatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen | 2007 |
Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer.
Topics: Adenoviridae; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; Doxorubicin; Etoposide; Fluorouracil; Humans; Male; Paclitaxel; Prostatic Neoplasms; RNA, Catalytic; Stathmin | 2006 |
Evidence of a novel antiapoptotic factor: role of inhibitor of differentiation or DNA binding (Id-1) in anticancer drug-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Hepatocellular; Catechin; Cell Line, Tumor; Cell Survival; Cisplatin; Down-Regulation; Doxorubicin; Etoposide; Female; HeLa Cells; Humans; Inhibitor of Differentiation Protein 1; Liver Neoplasms; Male; Mechlorethamine; Methotrexate; Mitomycin; Nasopharyngeal Neoplasms; Paclitaxel; Prostatic Neoplasms; Vincristine | 2007 |
Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Burkitt Lymphoma; Carcinoma; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Concanavalin A; Cytotoxicity, Immunologic; Diphosphonates; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Genes, T-Cell Receptor delta; Genes, T-Cell Receptor gamma; Humans; Imidazoles; Interferon-gamma; Lovastatin; Lung Neoplasms; Male; Membrane Glycoproteins; Neoplasms; Perforin; Pore Forming Cytotoxic Proteins; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Urinary Bladder Neoplasms; Vincristine; Zoledronic Acid | 2007 |
Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Estramustine; Etoposide; Humans; Leukopenia; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Thrombocytopenia | 2007 |
Loss of mitochondrial membrane potential is inhibited by bombesin in etoposide-induced apoptosis in PC-3 prostate carcinoma cells.
Topics: Analysis of Variance; Apoptosis; Bombesin; Cell Line, Tumor; Cell Survival; Confidence Intervals; Etoposide; Humans; Kinetics; Male; Membrane Potential, Mitochondrial; Microscopy, Confocal; Mitochondria; Prostatic Neoplasms | 2007 |
Methylseleninic acid enhances the effect of etoposide to inhibit prostate cancer growth in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Gene Expression; Gene Expression Profiling; Humans; Male; Metabolic Networks and Pathways; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Organoselenium Compounds; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Taxoids; Xenograft Model Antitumor Assays | 2007 |
Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line.
Topics: Androgen Antagonists; Androgens; Animals; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Etoposide; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Receptors, Androgen; RNA, Small Interfering; STAT3 Transcription Factor | 2007 |
Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Docetaxel; Estramustine; Etoposide; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Nephrostomy, Percutaneous; Nitriles; Phenotype; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tosyl Compounds; Transurethral Resection of Prostate; Urinary Diversion | 2007 |
Expression of androgen receptor is negatively regulated by p53.
Topics: 5' Untranslated Regions; Adenocarcinoma; Androgens; Bone Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; Consensus Sequence; DNA, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Male; Neoplasms, Hormone-Dependent; Osteosarcoma; Promoter Regions, Genetic; Prostatic Neoplasms; Receptors, Androgen; RNA, Small Interfering; Transfection; Tumor Suppressor Protein p53 | 2007 |
Anticancer effect of combination therapy of VP16 and fosfesterol in hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diethylstilbestrol; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Salvage Therapy; Survival Analysis | 2008 |
Prostate small cell carcinoma and skin metastases: a rare entity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Fatal Outcome; Humans; Male; Middle Aged; Prognosis; Prostatic Neoplasms; Skin Neoplasms; Vincristine | 2008 |
Prolonged survival using anti-CD20 combined chemotherapy in primary prostatic intravascular large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Epirubicin; Etoposide; Fatal Outcome; Humans; Ifosfamide; Lymphoma, B-Cell; Male; Prostatectomy; Prostatic Neoplasms; Rituximab; Survival | 2008 |
Phase II trial of etoposide in advanced prostate cancer.
Topics: Aged; Bone Marrow Diseases; Drug Evaluation; Etoposide; Humans; Infusions, Parenteral; Male; Middle Aged; Podophyllotoxin; Prostatic Neoplasms | 1984 |
[Effect of etoposide for pulmonary metastases from urogenital tract cancer].
Topics: Adenocarcinoma; Administration, Oral; Aged; Carcinoma, Transitional Cell; Etoposide; Humans; Infusions, Parenteral; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin; Prostatic Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms | 1984 |
Response of the Dunning R3327H prostatic adenocarcinoma to radiation and various chemotherapeutic drugs.
Topics: Adenocarcinoma; Animals; Cisplatin; Estramustine; Etoposide; Female; Male; Neoplasm Transplantation; Prostatic Neoplasms; Rats; Vincristine | 1982 |
Primary seminoma of the prostate.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Male; Prostatic Neoplasms; Seminoma | 1995 |
Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Carcinoma; Cell Division; Cisplatin; DNA Primers; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Immunologic Techniques; In Vitro Techniques; Interleukin-6; Male; Molecular Sequence Data; Prostatic Neoplasms; RNA, Messenger; Tumor Cells, Cultured | 1995 |
Reversal by a dihydropyridine derivative of non-P-glycoprotein-mediated multidrug resistance in etoposide-resistant human prostatic cancer cell line.
Topics: Cell Line; Dihydropyridines; Drug Resistance, Multiple; Etoposide; Humans; Male; Prostatic Neoplasms; RNA, Messenger; Sulfur Compounds; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1995 |
[Comparative study on urinary parameters reflecting renal damage during chemotherapy for urological cancer].
Topics: Acetylglucosaminidase; Adolescent; Adult; Aged; Aminopeptidases; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; CD13 Antigens; Cisplatin; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Etoposide; Humans; Ifosfamide; Kidney Diseases; Male; Methotrexate; Middle Aged; Prostatic Neoplasms; Proteinuria; Urinary Bladder Neoplasms; Vincristine | 1993 |
Extrapulmonary small cell carcinoma: a single-institution experience and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Laryngeal Neoplasms; Male; Middle Aged; Prostatic Neoplasms; Remission Induction; Retrospective Studies; Urinary Bladder Neoplasms | 1994 |
Relationships between proto-oncogene expression and apoptosis induced by anticancer drugs in human prostate tumor cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cisplatin; Drug Resistance; Etoposide; Gene Expression Regulation; Humans; Male; Prostatic Neoplasms; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogenes; Tumor Cells, Cultured | 1995 |
Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells.
Topics: Apoptosis; Base Sequence; Cell Survival; Dihydrotestosterone; Drug Interactions; Etoposide; Humans; Immunohistochemistry; Male; Molecular Sequence Data; Oligonucleotides, Antisense; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 1995 |
Effect of flutamide withdrawal on response assessment of estramustine and etoposide for prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Estramustine; Etoposide; Flutamide; Humans; Male; Prostatic Neoplasms | 1995 |
Combination chemotherapy in advanced prostate cancer: a silk purse?
Topics: Antineoplastic Combined Chemotherapy Protocols; Estramustine; Etoposide; Humans; Male; Prostatic Neoplasms | 1994 |
Oral etoposide in the treatment of hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Drug Administration Schedule; Drug Resistance; Etoposide; Humans; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Remission Induction; Survival Rate | 1994 |
[Surgical neoadjuvant chemo-hormonal therapy for advanced prostatic carcinoma].
Topics: Aged; Chemotherapy, Adjuvant; Cystectomy; Diethylstilbestrol; Drug Administration Schedule; Etoposide; Humans; Lymph Node Excision; Male; Middle Aged; Pelvic Exenteration; Prostatectomy; Prostatic Neoplasms; Urinary Diversion | 1994 |
[Leiomyosarcoma of the prostate: response to treatment with cisplatin, etoposide and methotrexate chemotherapy: a case report].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Leiomyosarcoma; Lung Neoplasms; Male; Methotrexate; Prostatic Neoplasms | 1994 |
Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line; Cell Line, Transformed; DNA; DNA, Neoplasm; Epithelial Cells; Etoposide; Female; Genes, ras; Humans; Male; Nucleosomes; Prostatic Neoplasms; Rats; Recombinant Proteins; Transforming Growth Factor beta; Tumor Cells, Cultured | 1993 |
Suramin inhibits DNA damage in human prostate cancer cells treated with topoisomerase inhibitors in vitro.
Topics: Amsacrine; Camptothecin; Cell Survival; Chemical Precipitation; DNA Damage; Dose-Response Relationship, Drug; Drug Interactions; Etoposide; Humans; Male; Prostatic Neoplasms; Suramin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1993 |
Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; DNA, Neoplasm; Drug Screening Assays, Antitumor; Estramustine; Etoposide; In Vitro Techniques; Male; Nuclear Matrix; Prostate; Prostatic Neoplasms; Rats; Tumor Cells, Cultured | 1993 |
Downregulation of protein kinase C suppresses induction of apoptosis in human prostatic carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinogens; Carcinoma; Cell Adhesion; Down-Regulation; Enzyme Activation; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Male; Melphalan; Phorbol Esters; Prostatic Neoplasms; Protein Kinase C; Tumor Cells, Cultured | 1996 |
Genesis of discrete higher order DNA fragments in apoptotic human prostatic carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Bleomycin; Cell Adhesion; Cell Line; Cyclophosphamide; DNA Topoisomerases, Type II; DNA, Neoplasm; Dose-Response Relationship, Drug; Electrophoresis; Etoposide; Humans; Kinetics; Male; Melphalan; Molecular Weight; Nucleosomes; Prostatic Neoplasms; Tumor Cells, Cultured | 1996 |
Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Cell Division; Cell Survival; Cells, Cultured; Estramustine; Etoposide; Humans; Male; Paclitaxel; Prostatic Neoplasms; Rats | 1996 |
Etoposide, epirubicin and carboplatin in hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Castration; Drug Resistance; Epirubicin; Etoposide; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Survival Rate | 1996 |
Secondary acute myelogenous leukemia following treatment with oral etoposide.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Etoposide; Humans; Leukemia, Myeloid, Acute; Male; Neoplasms, Second Primary; Prostatic Neoplasms | 1996 |
[A pilot study of low dose etoposide therapy for recurrenced prostate cancer in complicated over 75 years old stage D2 cases].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Bone Neoplasms; Drug Administration Schedule; Etoposide; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Pilot Projects; Prostatic Neoplasms | 1996 |
Induction of apoptosis in malignant and camptothecin-resistant human cells.
Topics: Androgens; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Cell Cycle; Cell Cycle Proteins; DNA Topoisomerases, Type I; Drug Interactions; Drug Resistance; Enzyme Inhibitors; Etoposide; Humans; Male; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Suramin; Tumor Cells, Cultured | 1996 |
Multidrug resistance in androgen-independent growing rat prostate carcinoma cells is mediated by P-glycoprotein.
Topics: Androgens; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Fluorescent Dyes; Genes, MDR; Male; Methotrexate; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Rats; Rhodamine 123; Rhodamines; Tumor Cells, Cultured; Verapamil; Vinblastine | 1997 |
DNase I primary transcript is alternatively spliced in both normal and apoptotic cells: no evidence of up-regulation in apoptosis.
Topics: 3T3 Cells; Adenocarcinoma; Alternative Splicing; Animals; Apoptosis; Breast Neoplasms; Cell Line; Deoxyribonuclease I; Etoposide; Exons; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Jurkat Cells; Liver Neoplasms, Experimental; Male; Mice; PC12 Cells; Polymerase Chain Reaction; Prostatic Neoplasms; Rats; Transcription, Genetic; Tumor Cells, Cultured; Up-Regulation | 1997 |
[Histopathological effect of neoadjuvant chemohormonal therapy for prostatic cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Diethylstilbestrol; Etoposide; Gonadotropin-Releasing Hormone; Humans; Male; Prostatectomy; Prostatic Neoplasms; Treatment Outcome | 1997 |
Antisense TR3 orphan receptor can increase prostate cancer cell viability with etoposide treatment.
Topics: Androgens; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Northern; Calcimycin; Cell Survival; DNA-Binding Proteins; Etoposide; Humans; Male; Metribolone; Nuclear Receptor Subfamily 4, Group A, Member 1; Orchiectomy; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Receptors, Thyroid Hormone; Transcription Factors; Transfection | 1998 |
Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis.
Topics: Animals; Antibodies; Antineoplastic Agents; Apoptosis; Cell Survival; Cisplatin; Cytotoxicity, Immunologic; Doxorubicin; Drug Synergism; Etoposide; Fas Ligand Protein; fas Receptor; Humans; Immunotherapy; Male; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Prostatic Neoplasms; T-Lymphocytes, Cytotoxic; Tumor Cells, Cultured | 1997 |
In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Gemcitabine; Humans; Male; Paclitaxel; Prostatic Neoplasms; Sarcoma; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 1998 |
Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity.
Topics: Antigens, CD; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cisplatin; Cyclohexenes; Cytokine Receptor gp130; Drug Resistance, Neoplasm; Etoposide; Genistein; Humans; Interleukin-6; Male; Membrane Glycoproteins; Monoterpenes; Oncostatin M; Peptides; Prostatic Neoplasms; Signal Transduction; Terpenes; Tumor Cells, Cultured | 1999 |
Etoposide sensitivity of human prostatic cancer cell lines PC-3, DU 145 and LNCaP.
Topics: Androgens; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Division; Cell Survival; Etoposide; Humans; Kinetics; Male; Nucleic Acid Synthesis Inhibitors; Prostatic Neoplasms; Tumor Cells, Cultured | 1999 |
Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Dose-Response Relationship, Drug; Drug Synergism; Estramustine; Etoposide; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Suramin; Tumor Cells, Cultured; Vinblastine | 1999 |
Establishment and characterization of a prostatic small-cell carcinoma cell line (PSK-1) derived from a patient with Klinefelter syndrome.
Topics: Adult; Animals; Antineoplastic Agents; Carcinoma, Small Cell; Cell Division; Cisplatin; Dacarbazine; Doxorubicin; Etoposide; Fluorouracil; Humans; Karyotyping; Klinefelter Syndrome; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Phosphopyruvate Hydratase; Prostatic Neoplasms; Tumor Cells, Cultured | 2000 |
p53 regulates the expression of the tumor suppressor gene maspin.
Topics: Adenoviridae; Antineoplastic Agents; Breast Neoplasms; DNA Damage; DNA-Binding Proteins; Etoposide; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Male; Neoplasm Metastasis; Promoter Regions, Genetic; Prostatic Neoplasms; Proteins; RNA, Messenger; Serpins; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Ultraviolet Rays | 2000 |
Extrapulmonary small-cell carcinoma: report of three cases and update of therapy and prognosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Esophageal Neoplasms; Etoposide; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Prostatic Neoplasms; Radiotherapy, Adjuvant | 2000 |
Doxazosin: a new cytotoxic agent for prostate cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxazosin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Humans; Male; Paclitaxel; Prostatic Neoplasms; Tumor Cells, Cultured | 2000 |
Rapid in vivo monitoring of chemotherapeutic response using weighted sodium magnetic resonance imaging.
Topics: Animals; Annexin A5; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Nucleus; Docetaxel; Etoposide; Flow Cytometry; Fluorescent Antibody Technique; Fluorescent Dyes; Humans; Magnetic Resonance Imaging; Male; Mice; Neoplasm Transplantation; Paclitaxel; Phantoms, Imaging; Prostatic Neoplasms; Sodium; Sodium Chloride; Taxoids; Time Factors; Treatment Outcome; Tumor Cells, Cultured | 2000 |
Activation of the tumor metastasis suppressor gene, KAI1, by etoposide is mediated by p53 and c-Jun genes.
Topics: 5' Untranslated Regions; Antigens, CD; Chloramphenicol O-Acetyltransferase; Dose-Response Relationship, Drug; Etoposide; Gene Expression; Genes, Reporter; Humans; Kangai-1 Protein; Lung Neoplasms; Male; Membrane Glycoproteins; Neoplasm Invasiveness; Neoplasm Metastasis; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-jun; Regulatory Sequences, Nucleic Acid; Transcription Factor AP-1; Transcription, Genetic; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2000 |
Heat-shock proteins inhibit induction of prostate cancer cell apoptosis.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Blotting, Western; Cycloheximide; Etoposide; Glutathione; Glutathione Transferase; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; HSP72 Heat-Shock Proteins; Humans; Kinetics; Male; Maleates; Molecular Chaperones; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nucleic Acid Synthesis Inhibitors; Prostatic Neoplasms; Protein Synthesis Inhibitors; Proto-Oncogene Proteins c-bcl-2; Radiation Tolerance; Tumor Cells, Cultured | 2000 |
Neuropeptides bombesin and calcitonin induce resistance to etoposide induced apoptosis in prostate cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bombesin; Calcitonin; Drug Resistance, Neoplasm; Etoposide; Humans; Male; Prostatic Neoplasms; Tumor Cells, Cultured | 2000 |
Seminoma metastatic to the prostate resulting in a rectovesical fistula.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Etoposide; Humans; Male; Prostatic Neoplasms; Rectal Fistula; Seminoma; Testicular Neoplasms; Urinary Bladder Fistula | 2000 |
A potential role of nuclear matrix-associated protein kinase CK2 in protection against drug-induced apoptosis in cancer cells.
Topics: Adenocarcinoma; Animals; Apoptosis; Casein Kinase II; Catalytic Domain; Cell Compartmentation; Cytoprotection; Cytosol; Diethylstilbestrol; DNA, Neoplasm; Etoposide; Female; Humans; Male; Mammary Neoplasms, Animal; Mice; Nuclear Matrix; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Protein Transport; Recombinant Proteins; Subcellular Fractions | 2001 |
Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Butylated Hydroxyanisole; Carcinogens; Cisplatin; DNA Fragmentation; Dose-Response Relationship, Drug; Doxorubicin; Enzyme-Linked Immunosorbent Assay; Etoposide; Female; Flow Cytometry; Humans; Male; Ovarian Neoplasms; Oxides; Prostatic Neoplasms; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 2000 |
Neoadjuvant estramustine and etoposide followed by concurrent estramustine and definitive radiotherapy for locally advanced prostate cancer: feasibility and preliminary results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Estramustine; Etoposide; Feasibility Studies; Humans; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation-Protective Agents; Radiotherapy, Conformal; Survival Analysis | 2001 |
Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice.
Topics: Animals; Antibodies, Monoclonal; Apoptosis; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Etoposide; Humans; Immunoglobulin G; Interleukin-6; Male; Mice; Mice, Nude; Prostatic Neoplasms; Time Factors; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
X-ray microanalysis of etoposide-induced apoptosis in the PC-3 prostatic cancer cell line.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Division; Cell Size; Cell Survival; DNA, Neoplasm; Electron Probe Microanalysis; Etoposide; Flow Cytometry; Humans; Male; Microscopy, Electron, Scanning; Prostatic Neoplasms; Tumor Cells, Cultured | 2001 |
Priming prostate carcinoma cells for increased apoptosis is associated with up-regulation of the caspases.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma; Caspases; Etoposide; Genes, bcl-2; Glutathione; Humans; Immunotherapy; Intracellular Fluid; Male; Maleates; Prostatic Neoplasms; Radiotherapy; Sulfhydryl Compounds; Tumor Cells, Cultured; Up-Regulation | 2001 |
[Globalization of anti-cancer therapies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Stomach Neoplasms | 2002 |
Neuropeptides bombesin and calcitonin inhibit apoptosis-related elemental changes in prostate carcinoma cell lines.
Topics: Absorptiometry, Photon; Antineoplastic Agents, Phytogenic; Apoptosis; Bombesin; Calcitonin; Calcium; Cell Division; Drug Resistance, Neoplasm; Etoposide; Flow Cytometry; Formazans; Humans; In Situ Nick-End Labeling; Male; Phosphorus; Potassium; Prostatic Neoplasms; Sodium; Sulfur; Tumor Cells, Cultured | 2002 |
Protein kinase Cdelta amplifies ceramide formation via mitochondrial signaling in prostate cancer cells.
Topics: Acetophenones; Antineoplastic Agents, Phytogenic; Apoptosis; Benzopyrans; Caspase Inhibitors; Caspases; Cell Fractionation; Ceramides; Enzyme Inhibitors; Etoposide; Flow Cytometry; Humans; Isoenzymes; Male; Mitochondria; Paclitaxel; Prostatic Neoplasms; Protein Kinase C; Protein Kinase C-delta; Signal Transduction; Sphingomyelins; Tumor Cells, Cultured | 2002 |
N-acetyl-L-cysteine enhances chemotherapeutic effect on prostate cancer cells.
Topics: Acetylcysteine; Antineoplastic Agents; Cisplatin; Etoposide; Humans; Interleukin-6; Male; NF-kappa B; Prostatic Neoplasms; Tumor Cells, Cultured | 2002 |
Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Animals; Coleoptera; Etoposide; Histone Acetyltransferases; Humans; Male; Mice; Nitriles; Nuclear Receptor Coactivator 1; Nuclear Receptor Coactivator 2; Prostate-Specific Antigen; Prostatic Neoplasms; Rabbits; Receptors, Androgen; Recombinant Fusion Proteins; Tosyl Compounds; Transcription Factors; Transcription, Genetic; Transfection | 2002 |
Ciprofloxacin inhibits cell growth and synergises the effect of etoposide in hormone resistant prostate cancer cells.
Topics: Anti-Infective Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Cell Division; Ciprofloxacin; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Down-Regulation; Drug Synergism; Electrophoretic Mobility Shift Assay; Etoposide; Gene Expression Regulation; Humans; Male; Middle Aged; NF-kappa B; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Radiation Tolerance; Tumor Cells, Cultured | 2002 |
Nonredundant antioxidant defense by multiple two-cysteine peroxiredoxins in human prostate cancer cells.
Topics: Animals; Antibody Specificity; Antineoplastic Agents; Antioxidants; Cysteine; Doxorubicin; Etoposide; Humans; Hydrogen Peroxide; Immune Sera; Male; Mice; Oxidative Stress; Paclitaxel; Peroxidases; Peroxiredoxin III; Peroxiredoxins; Prostatic Neoplasms; Protein Isoforms; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |
[Therapeutic experiences using the new podophyllotoxin derivative VP 16-213 in malignant human tumors].
Topics: Adenocarcinoma; Bronchial Neoplasms; Carcinoma; Carcinoma, Small Cell; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Podophyllotoxin; Prostatic Neoplasms; Remission, Spontaneous | 1975 |
[Thermochemotherapy of prostatic cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Bleomycin; Carcinoma, Squamous Cell; Drug Administration Schedule; Etoposide; Evaluation Studies as Topic; Humans; Hyperthermia, Induced; Male; Middle Aged; Peplomycin; Prostatic Neoplasms | 1991 |
[Preliminary report on the effect of etoposide or etoposide and CDDP on recurrent prostate cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Etoposide; Humans; Male; Neoplasm Recurrence, Local; Prostatic Neoplasms | 1991 |
[Intra-arterial infusion chemotherapy for advanced bladder cancer and prostate cancer using reservoir system].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Epirubicin; Etoposide; Female; Humans; Infusion Pumps; Infusions, Intra-Arterial; Male; Middle Aged; Prognosis; Prostatic Neoplasms; Urinary Bladder Neoplasms | 1991 |
[Study on etoposide therapy of relapsing prostatic cancer patients].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Drug Administration Schedule; Drug Evaluation; Etoposide; Humans; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Prostatic Neoplasms | 1990 |
[Trial of the hyperthermia treatment of prostatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Etoposide; Humans; Hyperthermia, Induced; Male; Middle Aged; Peplomycin; Prostatic Neoplasms; Radio Waves | 1988 |
[Chemotherapy of carcinoma of the prostate and testis: experimental study in vivo and in vitro].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Line; Cisplatin; Cytarabine; Etoposide; Fluorouracil; Male; Methotrexate; Mice; Mice, Nude; Neoplasm Transplantation; Peplomycin; Prostatic Neoplasms; Testicular Neoplasms; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vinblastine; Vincristine | 1988 |
[A multimodal treatment of prostatic carcinoma and the 5-year survival rate].
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Drug Administration Schedule; Estrogens; Etoposide; Humans; Male; Middle Aged; Neoplasm Staging; Orchiectomy; Prostatic Neoplasms | 1989 |
[Phase II study of etoposide (VP-16-213) in genitourinary tumors. VP-16-213 Genitourinary Study Group].
Topics: Adult; Aged; Alopecia; Anorexia; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Male; Middle Aged; Nausea; Podophyllotoxin; Prostatic Neoplasms; Testicular Neoplasms; Urinary Bladder Neoplasms; Urogenital Neoplasms | 1986 |
[Rhabdomyosarcoma of the prostate].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dactinomycin; Etoposide; Humans; Male; Middle Aged; Prostatic Neoplasms; Rhabdomyosarcoma; Vincristine | 1986 |
Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease.
Topics: Adenocarcinoma; Cell Line; Drug Evaluation; Drug Resistance; Etoposide; Hormones; Humans; Male; Prostatic Neoplasms; Tumor Stem Cell Assay | 1986 |
[Effect of etoposide for urogenital tumors].
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Pancreatic Neoplasms; Podophyllotoxin; Prostatic Neoplasms; Rhabdomyosarcoma; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urogenital Neoplasms | 1985 |
[Collaborative phase II study of etoposide (NK-171). Urological Cooperative Study Group of etoposide (NK-171)].
Topics: Administration, Oral; Alopecia; Anorexia; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Infusions, Parenteral; Kidney Neoplasms; Male; Nausea; Podophyllotoxin; Prostatic Neoplasms; Testicular Neoplasms; Urogenital Neoplasms | 1985 |